“Very efficient and courteous staff. Dr. is thorough, helpful, explained clearly, answered questions. Appointment soon as new patient. Will see him annually.”
Blood Thinners and Eye Injections: What You Need to Know Before Your Visit
What an Intravitreal Injection Actually Is
Many patients picture something very different from what an eye injection actually involves. Understanding the procedure helps explain why bleeding concerns are manageable for most people on blood thinners.
An intravitreal injection places medicine directly into the vitreous cavity, which is the gel-filled space at the back of the eye. The needle enters through the white part of the eye called the sclera, a few millimeters behind the colored part. It is carefully positioned to avoid the lens at the front and the retina at the back. The procedure takes about ten to fifteen minutes total, and most patients feel pressure rather than pain.
Most of the appointment is preparation. The eye is numbed with anesthetic drops or gel, then cleaned thoroughly with a povidone-iodine solution. A small lid holder keeps the eye open. The iodine step is the one patients notice most, and it is also the most important step because it reduces the risk of infection, which is a greater concern than bleeding for most patients.
The needle crosses the outer coat of the eye, which is a firm, tough layer covered by a thin film of small surface vessels. Nicking one of these surface vessels produces a bright red patch on the white of the eye. This looks alarming but is harmless. The vessels that could cause sight-threatening bleeding sit deeper, in the retina and the layer beneath it, and the injection path is carefully planned to stay clear of them. That anatomy is the main reason serious bleeding after a routine injection is uncommon, even in patients on blood thinners.
What the Evidence Shows About Injecting While on a Blood Thinner
Research on this topic has grown significantly, and the picture is reassuring for most patients, though not without nuance. Two key studies offer important and complementary perspectives.
A widely referenced retrospective study followed 520 patients through more than 3,100 anti-VEGF injections. The patients included those taking warfarin, clopidogrel, aspirin, and combinations of these. The study recorded no hemorrhagic complications inside the eye in any of those groups, and the authors recommended continuing medications without stopping them, specifically because of the clotting risk that comes with stopping. This study is frequently cited in clinical settings and remains an important reference point.
A more recent nationwide study of nearly 95,000 people with wet age-related macular degeneration found a different signal. Among patients studied, those taking anticoagulant medications had higher odds of experiencing a bleed inside the eye serious enough to require surgical treatment. The odds were also elevated for antiplatelet drugs, and highest when both drug types were taken together. These are relative figures, meaning they describe a comparison rather than a common outcome, and serious bleeding requiring surgery remains uncommon overall.
These two studies are answering slightly different questions, and both contribute something useful. The first asked whether the injection itself causes serious bleeding in patients on blood thinners. The second asked whether patients on these medications experience higher rates of serious bleeding over years of treatment for a disease that already involves abnormal blood vessels in the eye. The authors of the larger study did not recommend stopping these medications. They called for closer monitoring and better communication between treating physicians. For most patients, the practical result is not a change in what you swallow each morning, but a change in how closely your team watches for bleeding-related changes at follow-up visits.
What Blood Thinners Are, and How They Differ
The term 'blood thinner' covers two different families of medications that work in different ways. Understanding the difference can help you have a more useful conversation with both your Retina Specialist and your prescribing physician.
Anticoagulants slow the chemical cascade that causes blood to clot. Warfarin is the most familiar example. Newer direct oral anticoagulants, sometimes called DOACs or NOACs, work on specific steps in the same process and include drugs prescribed for atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Clear guidelines for managing these newer agents around eye procedures are still evolving, which is why individual assessment by your prescribing physician matters so much.
Antiplatelet drugs prevent the tiny blood cells called platelets from sticking together to form a clot. Aspirin is the most common example and is often taken in low doses for heart protection. Clopidogrel is another frequently prescribed antiplatelet, often used after a heart attack or stent placement. Many patients do not think of aspirin as a blood thinner when filling out medical forms, but it is important to disclose it. The research treats antiplatelet and anticoagulant drugs separately, and the combination of both carries a different profile than either alone.
The drug name alone does not tell the full story. The reason behind the prescription determines how serious the risk of stopping really is. A person taking warfarin to protect a mechanical heart valve faces a very different risk profile from someone taking low-dose aspirin for general cardiovascular prevention. Patients with a mechanical heart valve, a recent coronary stent, a recent blood clot in the leg or lung, or atrial fibrillation should be especially clear with both their Retina Specialist and their prescribing doctor about their specific indication, because unsupervised pausing in these situations carries serious consequences.
Who Continues, Who May Be Asked to Pause, and What to Discuss Before Injection Day
For most patients receiving intravitreal injections, the standard approach is to continue taking their blood thinner without any changes. When pausing does come up, it is almost always in the context of eye surgery rather than a routine injection.
The most common outcome of a pre-injection consultation is that nothing about your blood thinner changes at all. Your Retina Specialist documents what you take, notes it in your chart, and proceeds with the injection. You may be told to expect a redder eye than usual afterward. Knowing this in advance means you will not be alarmed when you see it in the mirror.
Pausing or adjusting blood thinners is more commonly considered for eye surgeries than for routine injections. Procedures vary by their bleeding risk. Cataract surgery is considered very low risk. Retinal and glaucoma operations fall at an intermediate level. More extensive procedures, such as orbital surgery, carry higher bleeding risk and may involve longer hold periods. If someone mentions a hold period to you, ask which specific procedure and which specific medication they are referring to. Those details determine whether the guidance applies to your situation.
Come prepared with a current written medication list rather than relying on memory. Include over-the-counter products like aspirin and fish oil, which are easy to forget but relevant to this conversation. Note who prescribes each medication and why, since the indication matters more than the drug name. If you have ever had bleeding inside the eye, or if you have a known bleeding disorder, mention it before you are asked. The more complete your picture, the more precisely your team can plan your care.
What Is Normal After an Injection and What Needs Attention
Knowing what to expect after an intravitreal injection helps you respond appropriately if something changes. Most of what you will notice is ordinary and expected. A small number of signs require prompt contact with our office.
Grittiness, mild soreness, and blurry vision for a few hours are common and come mostly from the iodine preparation and the lid holder rather than the needle itself. Floaters may appear and typically settle within a day or two. Plan not to drive yourself home after your first injection until you know how your vision responds. These normal reactions typically resolve on their own without any treatment.
A bright red patch on the white of the eye is one of the most noticeable things that can happen after an injection, and it is the thing blood thinners are most likely to make more pronounced. It is blood trapped under the clear surface membrane called the conjunctiva, not inside the eye itself. It tends to look worse over the first two days as it spreads slightly, then gradually fades through a range of colors over about a week. It does not affect vision and is not painful. If your eye is red and also painful, or if your vision changes, that combination is a reason to call us the same day.
Across a large review covering tens of thousands of injections, the total complication rate was below two in every one hundred injections, and the majority of those complications were minor and resolved on their own. Infection inside the eye is the most serious risk and occurs in a very small fraction of injections. Retinal detachment directly caused by an injection is also rare. These figures apply to intravitreal injections in general and are not specific to patients on blood thinners. They exist to give context to the recommendation for treatment, which is always made because the underlying retinal disease poses a greater threat to vision than the procedure itself.
Frequently Asked Questions
These answers are meant to help you think through your specific situation and arrive at your appointment better prepared.
Ask your Retina Specialist to put their recommendation in writing, including what they are proposing and the reason for it, and take that document to your cardiologist or prescribing physician. The most efficient path is for the two offices to speak directly rather than having you relay information between them. When they are aligned, you will have a clear, coordinated plan rather than conflicting instructions. This kind of communication is a normal part of managing patients on blood thinners, and our team is experienced in facilitating it.
Call the office that prescribes it today, not at your next scheduled appointment. Tell them how many doses you missed and when. Do not simply double up to make up for missed doses unless you are specifically told to do so. Restarting is usually straightforward, and for many people it is a routine phone call rather than an emergency. The urgency depends on why you are taking the medication in the first place, which is another reason to call rather than wait.
Yes, it falls into the antiplatelet category and your Retina Specialist will want to know about it. Aspirin is frequently omitted from medication lists because patients do not think of it as a prescription drug. While low-dose aspirin sits at the gentler end of the antithrombotic spectrum, research shows it still plays a role in the overall picture, especially when combined with a stronger anticoagulant. Disclose it and let your team factor it in, but do not stop it on your own before getting guidance.
Make this clear at the start of your consultation, because the combination is where the evidence is least straightforward. Research indicates that taking an anticoagulant and an antiplatelet together is associated with higher odds of serious intraocular bleeding compared to taking either medication alone. That finding calls for closer monitoring and a more detailed conversation with your prescribing physician, not a unilateral decision to drop one of the medications. Patients on dual therapy are typically on it for a significant reason, and that reason matters.
The evidence contains a genuine gap, particularly around newer oral anticoagulants, and careful clinicians fill gaps using professional judgment rather than a single universal rule. What is consistent across well-run clinics is the process: the prescribing doctor decides whether to adjust the medication, the eye team documents what you are taking and monitors accordingly, and no one stops anything without that coordination. If the guidance you receive feels vague, ask for written documentation of exactly what is being recommended and why.
From a bleeding standpoint, the needle path and entry site are essentially the same, so the blood thinner considerations are broadly similar. Steroid injections do carry their own distinct set of monitoring concerns that are separate from bleeding risk, including effects on eye pressure, which your Retina Specialist will discuss with you. If your treatment is changing from one injection type to another, ask specifically what changes in your follow-up monitoring plan, rather than whether your tablets need to change.
Visit Atlantic Retina Center for Expert Retinal Care
Atlantic Retina Center is a single-specialty practice dedicated entirely to the retina, vitreous, and macula, serving patients across the Eastern Shore of Maryland and central and southern Delaware. Our ABO board-certified, fellowship-trained Retina Specialists have the focused expertise to manage complex conditions like yours with precision and care. We coordinate closely with your other physicians to make sure every aspect of your treatment, including how your blood thinners interact with your eye care, is handled thoughtfully and safely. We welcome you to schedule a consultation and experience the difference that true subspecialty care makes.